CN101607051B - 一种中药减肥组合物及其制备方法 - Google Patents
一种中药减肥组合物及其制备方法 Download PDFInfo
- Publication number
- CN101607051B CN101607051B CN2009100171697A CN200910017169A CN101607051B CN 101607051 B CN101607051 B CN 101607051B CN 2009100171697 A CN2009100171697 A CN 2009100171697A CN 200910017169 A CN200910017169 A CN 200910017169A CN 101607051 B CN101607051 B CN 101607051B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- medicine
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 151
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 241000903946 Clematidis Species 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 239000002775 capsule Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 241000545442 Radix Species 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 15
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 8
- 235000011837 pasties Nutrition 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 241001421953 Eclipta <beetle> Species 0.000 claims 4
- 241001529739 Prunella <angiosperm> Species 0.000 claims 4
- 239000009636 Huang Qi Substances 0.000 abstract description 12
- 235000006693 Cassia laevigata Nutrition 0.000 abstract description 5
- 244000286838 Eclipta prostrata Species 0.000 abstract description 5
- 244000179560 Prunella vulgaris Species 0.000 abstract description 5
- 229940124513 senna glycoside Drugs 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000167854 Bourreria succulenta Species 0.000 abstract 1
- 244000025596 Cassia laevigata Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000009811 Momordica charantia Nutrition 0.000 abstract 1
- 240000001910 Momordica cochinchinensis Species 0.000 abstract 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract 1
- 235000018365 Momordica dioica Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000011358 Patrinia scabiosaefolia Species 0.000 abstract 1
- 235000009267 Patrinia scabiosaefolia Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241000612118 Samolus valerandi Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 241001369613 Stephania tetrandra Species 0.000 abstract 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 1
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 235000019693 cherries Nutrition 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 75
- 210000004369 blood Anatomy 0.000 description 74
- 208000008589 Obesity Diseases 0.000 description 54
- 235000020824 obesity Nutrition 0.000 description 54
- 230000000694 effects Effects 0.000 description 48
- 239000003925 fat Substances 0.000 description 47
- 235000019197 fats Nutrition 0.000 description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 201000010099 disease Diseases 0.000 description 34
- 208000002193 Pain Diseases 0.000 description 33
- 241000282414 Homo sapiens Species 0.000 description 32
- 210000000952 spleen Anatomy 0.000 description 32
- 230000036407 pain Effects 0.000 description 31
- 239000000047 product Substances 0.000 description 31
- 230000037396 body weight Effects 0.000 description 24
- 210000002784 stomach Anatomy 0.000 description 24
- 235000013305 food Nutrition 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 230000036541 health Effects 0.000 description 19
- 230000017531 blood circulation Effects 0.000 description 18
- 235000005911 diet Nutrition 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 206010062717 Increased upper airway secretion Diseases 0.000 description 17
- 230000037213 diet Effects 0.000 description 17
- 208000026435 phlegm Diseases 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 208000006820 Arthralgia Diseases 0.000 description 14
- 206010012735 Diarrhoea Diseases 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 12
- 210000001015 abdomen Anatomy 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 206010010774 Constipation Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 208000033809 Suppuration Diseases 0.000 description 9
- 208000001848 dysentery Diseases 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 208000025747 Rheumatic disease Diseases 0.000 description 8
- 230000036528 appetite Effects 0.000 description 8
- 235000019789 appetite Nutrition 0.000 description 8
- 239000003172 expectorant agent Substances 0.000 description 8
- 230000003419 expectorant effect Effects 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 230000000552 rheumatic effect Effects 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000019790 abdominal distention Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000002894 beriberi Diseases 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 206010013990 dysuria Diseases 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000001047 pyretic effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- IPQVTOJGNYVQEO-CXZNLNCXSA-N sennoside A Natural products O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O5)cccc34)c2c1 IPQVTOJGNYVQEO-CXZNLNCXSA-N 0.000 description 5
- 206010040872 skin infection Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000201295 Euphrasia Species 0.000 description 4
- 206010020710 Hyperphagia Diseases 0.000 description 4
- 102000016267 Leptin Human genes 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 241000522641 Senna Species 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 4
- 229940039781 leptin Drugs 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 235000005686 eating Nutrition 0.000 description 3
- 230000007937 eating Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 229960001582 fenfluramine Drugs 0.000 description 3
- 239000003337 fertilizer Substances 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 102000012367 Beta 3 adrenoceptor Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000269417 Bufo Species 0.000 description 2
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 231100000293 acute skin toxicity Toxicity 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108040005346 beta3-adrenergic receptor activity proteins Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229930187479 gypenoside Natural products 0.000 description 2
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QZMAEZWZCGBZFK-AOJWCAIYSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2s,3r Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QZMAEZWZCGBZFK-AOJWCAIYSA-N 0.000 description 1
- ICWHTQRTTHCUHW-IPYPFGDCSA-N 2-[(3s,5r,6r)-6,10-dimethylspiro[4.5]dec-9-en-3-yl]propan-2-ol Chemical compound C[C@@H]1CCC=C(C)[C@]11C[C@@H](C(C)(C)O)CC1 ICWHTQRTTHCUHW-IPYPFGDCSA-N 0.000 description 1
- QZMAEZWZCGBZFK-UHFFFAOYSA-N 28-(beta-D-Glucopyranosyloxy)-28-oxoolean-12-en-3beta-yl 3-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosiduronic acid Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC(C1O)OC(C(O)=O)C(O)C1OC1OC(CO)C(O)C(O)C1O QZMAEZWZCGBZFK-UHFFFAOYSA-N 0.000 description 1
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 1
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 description 1
- ICWHTQRTTHCUHW-UHFFFAOYSA-N Agarospirol Natural products CC1CCC=C(C)C11CC(C(C)(C)O)CC1 ICWHTQRTTHCUHW-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- IRLNKOAURQPXIQ-WWWUCTDISA-N Apiopaeonoside Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc(OC)cc1 IRLNKOAURQPXIQ-WWWUCTDISA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241001649190 Campsis Species 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 244000098897 Chenopodium botrys Species 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- IDZZECHGWAZTIB-NYBIBFQCSA-N Paeonolide Chemical compound COC1=CC=C(C(C)=O)C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-NYBIBFQCSA-N 0.000 description 1
- IDZZECHGWAZTIB-WPQJODJHSA-N Paeonolide Natural products O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)CO3)O2)cc(OC)cc1 IDZZECHGWAZTIB-WPQJODJHSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100037205 Sal-like protein 2 Human genes 0.000 description 1
- 101710192308 Sal-like protein 2 Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000007230 Sorghum bicolor Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607757 Xenorhabdus Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- IDZZECHGWAZTIB-UHFFFAOYSA-N affinoside Natural products COC1=CC=C(C(C)=O)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)=C1 IDZZECHGWAZTIB-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960001877 fenfluramine hydrochloride Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013360 fish flour Nutrition 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- KPJWZUAARPJYSB-UHFFFAOYSA-N glycoside C Natural products CC1(C)OC(=O)C23CCC1C2(O)CCC(C1(CCC24)C)(C)C3CCC1C2(C)CCCC4(C)COC(C(C(O)C1O)OC2C(C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O KPJWZUAARPJYSB-UHFFFAOYSA-N 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical class [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- IPQVTOJGNYVQEO-AIFLABODSA-N sennoside B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-AIFLABODSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000022 skin irritation / corrosion Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- -1 tetracyclic triterpenoids compound Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000008843 wulingsan Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种中药减肥组合物及其制备方法,内服药物为:苍术10~20份,白术10~20份,大黄10~20份,当归10~20份,泽泻10~20份,丹皮10~20份,郁李仁10~20份,荷叶10~20份,绞股蓝10~20份,黄芪10~20份,枳壳10~20份,威灵仙10~20份,夏枯草10~20份,苦瓜10~20份,番泻叶10~20份,瓜蒌仁10~20份,山楂10~20份,羌活10~20份,薏仁10~20份;外用药物为:细辛10~30份,防己10~30份,冰片10~30份,旱莲草10~30份,丹参10~30份,附子10~30份,天南星10~30份,鸡血藤10~30份,鱼腥草10~30份,败酱草10~30份。本发明无副作用,疗效稳定。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物组份的医用配制品及其制备方法,特别涉及一种中药减肥组合物及其制备方法。
背景技术
中医早在《黄帝内经》就有记载,人有肥,有膏,有肉,指出肥胖的特点:身形肥胖,多脂,血液粘绸,运行缓慢此为高梁之疾也,肥胖之人多过食肥甘厚味,有碍脾胃,使脾失健运,水谷精微不能化生精血,而成膏脂痰浊内蓄,蓄于肌肤而成肥胖;脾胃实热消谷善肌,多食多饮而致气血有余,化膏脂而内蓄也会致肥;肝主疏泄,如果长期情志不舒则气结痰凝,或疏泄失调而致脾失健运,痰湿内生;肾主水,肾气虚则不能化气行水,而致湿浊内停,溢于肌肤,而致肥胖;年老体衰,五脏六腑功能减退,水谷精微不能正常输布也会造成湿浊内停而致肥胖。
现代医学研究表明,肥胖症已成为当今社会中引发各种疾病的根源,据统计数据表明,在肥胖人群中,90%的肥胖患者忠有高血压、高血脂、高血糖等三高病症;70%的肥胖患者患有冠心病、心血管疾病,同时有50%的患者会有痛风、胆石症、胆囊炎等症;78%的肥胖患者会转化成糖尿病、胰岛素缺乏症,其中又有90%的患者会出现急慢性胰腺炎等病症;90%的肥胖患者患有脑动脉硬化、脑血栓、脑动能微循环实调,其中多数会出现中风、偏瘫和肢体麻木等病症;老年性肥胖患者还会出现痴呆、失眠、健忘和骨质疏松等症。目前中国每年肥胖患者正以5%的比例增长,而且出现了向婴幼儿、儿童、青少年等低龄化发展的趋势,中国每年因治疗由肥胖症引发的各种疾病,已占到GDP的2~3%,由此可见,预防和治疗肥胖症也成为关系到人口健康和国家可持续发展的大事。
肥胖症是由于能量的摄人超过能量的消耗而导致人体脂肪的过多积累,使体内脂肪堆积过多,体重增加。确切的肥胖定义是指体内脂肪异常增多,而非体重的超标。根据病因,肥胖症可分为单纯性和继发性两类。单纯性肥胖是指只有肥胖而无任何器质性疾病的肥胖症。单纯性肥胖又可分为幼年起病的体质性肥胖和成年起病的获得性肥胖。单纯性肥胖可能与遗传因素、中枢神经系统的食欲调节、内分泌功能改变、代谢因素以及静坐、多食的生活习惯等有关。继发性肥胖多继发于某些疾病如下丘脑一垂体的炎症、肿瘤、创伤、皮质醇增多症、甲状腺功能减退症、性腺功能减退症、型糖尿病早期、胰岛素瘤等单纯性肥胖的病因和发病机制尚不完全清楚,可能与下列因素有关。遗传因素,流行病学显示某些肥胖者有家庭发病倾向。精神神经因素,动物实验和临床观察表明神经和精神因素对人的摄食有调节作用。内分泌因素,许多激素如甲状腺素、胰岛素、糖皮质激素等可能参与了肥胖症的发病机制。生活方式与饮食习惯,不爱活动的人消耗能量减少,易发生肥胖。运动员在停止运动后,经常摄人高热卡饮食或食量大、吸烟者在戒烟后、睡前进食习惯、喜欢吃油腻食物、每天进餐次数少而每餐进食量大等都与单纯性肥胖的发生有关,但都不是唯一病因。
肥胖病已成为危害人类健康长寿的大敌随着人们的医疗保健意识水平的不断提高,“肥胖”不再与“健康”划上等号,人们都认识到肥胖是导致多种疾病产生的根源。肥胖病在发达国家及发展中国家象瘟疫一样蔓延开来,发病率逐年攀升。据估算,世界上肥胖病患者目前至少有12亿。在美国和欧洲,肥胖患者大量增加。美国肥胖患者占总人口的1/2,造成每年约30万人死亡。世界卫生组织肥胖问题特别小组负责人菲利詹姆斯博士预测,世界上胖子人数将以每5年一倍的速度增加。肥胖与艾滋病、毒麻药瘾和酒癖,并列为世界四大医学社会问题,是人类健康长寿的大敌。医学界还把与肥胖有关的冠心病、高血压、高脂血症、糖尿病、脑血管意外称为“死亡五重奏”。因此,卫生部部长张文康指出:采取有效措施,科学地预防和治疗肥胖,已成为当今国内外普遍关注的热点,也是摆在我国医学界面前的新课题。我国肥胖患者已超过7000万人(不包括儿童肥胖),占总人口的5.4%。随着改革开放和人民物质生活条件改善,肥胖病患者正逐年增长,尤以大中城市发病率为高,约占城市人口的17%。在北京、上海等大城市,近1/3的成人体重超重,成为肥胖症的高发区。而近十年来,儿童肥胖检出率平均每年增长9%左右,这意味着10年后我国肥胖儿童的数量将比现在多一倍。
国内外减肥药物现状大多数减肥药物如食欲抑制剂、利尿剂、泻药等都有程度不等的副作用。目前世界上畅销的减肥药物主要有:德国(克诺)KNOLL药厂的西布曲明;瑞士罗氏公司的奥利司他。减肥这一概念的提出在中国不过是十来年的事,而减肥产品却已经过走了飞速发展的更新历程。20世纪90年代中期至今,减肥品市场已经经历了两次产品换代。第一代清泻型减肥产品大多将传统减肥茶进行了改良,利用茶叶祛脂化腻的功效来进行减肥。为了体现快速减肥的效果,一些厂家在减肥茶中加入了剂量不等的泻药如大黄、芒硝和蕃泻叶等中草药,通过腹泻的方式人体中的水分和蛋白质,造成的是体重减轻的假象,却未能触及肥胖的根本。长期服用这些减肥茶,还会对人体机能造成损害,出现习惯性腹泻、胃肠功能失调和人体失水等症状。第二代饥饿替代型减肥产品通过“节食”来达到减肥目的,即以低热量食品取代正常饮食,以减少人体对脂肪、糖类的摄入,依靠人体自身脂肪的消耗来补充能量。为了造成“吃饱”了的感觉,有些替代型减肥食品中还加入食欲抑制剂芬氟拉明、安菲拉酮等药物(目前在美国已停用)。长期使用会使身体处于饥饿状态,不但降低了机体各方面的活动能力,一旦停止服用,体重便会迅速反弹。第三代健康型减肥产品以世界卫生组织提出的不腹泻、不节食和不乏力为减肥原则,功效比第一代、第二代减肥产品有所提高。
目前,已认识到胰岛素和Leptin(瘦素)抵抗在肥胖症中充当了重要角色。近年来发现了肥胖基因的产物Leptin通过影响食欲和能量代谢调节体重。用重组Leptin治疗肥胖小鼠,能使摄食减少,体重减轻,降低血糖、血脂、皮质酮及胰岛素含量,因而成为近年研究肥胖减肥的热点之一。β3肾上腺素受体激动剂CL316243在肥胖和糖尿病的动物模型显示有抗肥胖、糖尿病,改善胰岛素抵抗作用。鉴此,β3肾上腺素受体激动剂的研究开发也是减肥药筛选的新思路。另外,从脂酶抑制剂(如orlistat)中寻找减肥药也是一有效途径。
在市场上预防和治疗肥胖症的药品、保健品可谓五花八门,种类繁多,这类产品中多以口服制剂为主,其减肥的原理是以抑制食欲和抑制油脂的吸收为手段,其中科学而又被患者普遍接受的方式就是调整人类的饮食结构,改善食品质量,减少人体对油脂、肉类、蛋类和糖类食品的摄入量,缺点是减少了人类对美味食物的充分享受。而这些通过口服减肥的药品、保健品有时会出现影响肝、肾、心脏等功能的副反应。同时医学研究表明,人体脂肪中的油脂,主要有两类化学物质组成,一类是饱和脂肪酸脂占脂肪油脂的79%,是属于不易被氧化、分解、代谢的物质,易于聚集在皮下的脂肪中,有时这类物质进入血管流通时,还易形成血栓凝聚物,阻塞血液流动性,增加血液的黏稠度,降低血流量,从而会产生脑供养不足,引发血管痉挛和收缩,导致冠心病、心血管疾病、脑动脉硬化、中风、偏瘫和痴呆等症。这也是肥胖患者发病的主要有害的物质。另一类是不饱和脂肪酸占总脂肪油脂的20%,是一类被人体吸收、转化的物质,也是人体各器官代谢要求的能量组份,同时这类成分在人体中还有抗炎、抗血液中血栓形成、抗心律失常、抗脑动脉硬化的功效,是对人体有益的物质。现代医学研究证实,不饱和脂肪酸还有预防冠心病、心血管疾病、糖尿病、癌症、肝炎、脑动脉硬化症、中风、偏瘫、痴呆抑郁症、神经分裂症、类风湿和风湿性关节炎、神经性皮炎、肺气肿、哮喘、肾炎等疾病的作用,而且这类物质还是人体大脑脂质体的重要组成物质。如何既不影响人类身体健康,又能有效控制脂肪达到美观和健康的目的是亟需解决的技术难题。
发明内容
本发明的减肥组合物从选方到产品制成,完全选用纯天然中药成份,对人体几乎没有任何副作用,且疗效稳定,不反弹。本发明解决了上述减肥药物副作用大,不宜长期使用且容易反弹的技术问题。
为解决上述技术问题,本发明提供了一种中药减肥组合物,其由内服药物和外用药物组成,所述内服药物中各种组份的重量份数比为:苍术10~20份,白术10~20份,大黄10~20份,当归10~20份,泽泻10~20份,丹皮10~20份,郁李仁10~20份,荷叶10~20份,绞股蓝10~20份,黄芪10~20份,枳壳10~20份,威灵仙10~20份,夏枯草10~20份,苦瓜10~20份,番泻叶10~20份,瓜蒌仁10~20份,山楂10~20份,羌活10~20份,薏仁10~20份;
所述外用药物中各种组份的重量份数比为:细辛10~30份,防己10~30份,冰片10~30份,旱莲草10~30份,丹参10~30份,附子10~30份,天南星10~30份,鸡血藤10~30份,鱼腥草10~30份,败酱草10~30份。
所述内服药物中各种组份的重量份数比可优选为:苍术10~15份,白术10~15份,大黄10~15份,当归10~15份,泽泻10~15份,丹皮10~15份,郁李仁10~15份,荷叶10~15份,绞股蓝10~15份,黄芪10~15份,枳壳10~20份,威灵仙10~20份,夏枯草10~20份,苦瓜10~20份,番泻叶10~20份,瓜蒌仁10~20份,山楂10~20份,羌活10~20份,薏仁10~20份;
所述外用药物中各种组份的重量份数比可优选为:细辛10~20份,防己10~20份,冰片10~20份,旱莲草10~20份,丹参10~20份,附子10~20份,天南星10~20份,鸡血藤10~20份,鱼腥草10~20份,败酱草10~20份。
所述内服药物中各种组份的重量份数比还可优选为:苍术10~20份,白术10~20份,大黄10~20份,当归10~20份,泽泻10~20份,丹皮10~20份,郁李仁10~20份,荷叶10~20份,绞股蓝10~20份,黄芪10~20份,枳壳10~15份,威灵仙10~15份,夏枯草10~15份,苦瓜10~15份,番泻叶10~15份,瓜蒌仁10~15份,山楂10~15份,羌活10~15份,薏仁10~15份;
所述外用药物中各种组份的重量份数比还可优选为:细辛15~25份,防己15~25份,冰片15~25份,旱莲草15~25份,丹参15~25份,附子15~25份,天南星15~25份,鸡血藤15~25份,鱼腥草15~25份,败酱草15~25份。
所述内服药物中各种组份的重量份数比也可优选为:苍术15~20份,白术15~20份,大黄15~20份,当归15~20份,泽泻15~20份,丹皮15~20份,郁李仁15~20份,荷叶15~20份,绞股蓝15~20份,黄芪15~20份,枳壳15~20份,威灵仙15~20份,夏枯草15~20份,苦瓜15~20份,番泻叶15~20份,瓜蒌仁15~20份,山楂15~20份,羌活15~20份,薏仁15~20份;
所述外用药物中各种组份的重量份数比也可优选为:细辛10~25份,防己10~25份,冰片10~25份,旱莲草10~25份,丹参10~25份,附子10~25份,天南星10~25份,鸡血藤10~25份,鱼腥草10~25份,败酱草10~25份。
为解决上述技术问题,本发明还提供了一种中药减肥组合物的制备方法,所述内服药物的剂型为胶囊剂,其制备方法包括以下步骤:
a.将所述组份粉碎后加入乙醇,加热回流提取3次;
b.将3次提取液合并,回收乙醇,浓缩抽滤后经吸附树脂柱吸附;
c.吸附后用去离子水或蒸馏水洗脱,再用乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到组份药粉,装入胶囊制为胶囊剂。
所述内服药物的制备方法,所述步骤a中,可以将所述组份粉碎后加入10倍量乙醇,加热回流提取3次,每次加热为2小时。
所述内服药物的制备方法,所述步骤b中,可以将3次提取液合并后,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08,所述滤液流经体积为10L的吸附树脂柱吸附。
所述内服制备方法,所述步骤c中,可以在吸附之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到组份药粉,装入胶囊制为胶囊剂。
为解决上述技术问题,本发明又提供了一种中药减肥组合物的制备方法,所述外用药物的剂型为涂抹剂,其制备方法包括以下步骤:
先将冰片研细备用;按照所述份数比将天南星,附子用95%乙醇浸泡三次,每次浸泡时间分别为2小时、1小时、1小时;每次浸泡后80~85℃热提取;所用乙醇与附子,天南星总重量相比分别为:第一次10倍量、第二次6倍量、第三次6倍量;合并三次乙醇提取液,浓缩至相对密度为1.08的浓缩液,静置备用,将所述剩余组份按配比混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温下,与乙醇共同浸渍15~30天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,将滤液与上述浓缩液合并加热,浓缩至糊状,放入烘箱烘干后冷却,研磨成细粉,加入冰片细粉和凡士林调和成糊状。
所述中药减肥组合物中内服药物的剂型可以为:蜜炼丸剂、水合丸剂、胶囊、片剂、糖浆剂、散剂、口服液体药物或凝胶剂;所述外用药物的剂型可以为:膏剂、贴剂或喷雾剂。
本发明的制成品与市场上的保健品、减肥茶相比较,有以下优点:1、减肥过程非常舒服,可在睡眠状态下进行。2、本品属纯中药制剂,不含任何毒性及刺激性或抑制食欲及影响人体正常运行、吸收、生长的物质,对人体无害。3、不含任何激素物质,不影响人体内分泌和腑脏功能的正常运行吸收。4、无任何副作用,不产生内分泌紊乱,不需过分节食,只要适当注意不要过分进食即可。5、疗效好,减肥的同时,还具有活血利湿、使肌肤变得更加细腻,令身体健美苗条。6、能够转化消除多余脂肪和因新陈代谢而潴留体内的水湿、不伤人体正气和生理功能,为人体推陈出新,促进新陈代谢,使形体健美且消除体内的垃圾,消除疾病隐患。是非常好的一种减肥瘦身保健的纯中药制剂。
具体实施方式
众所周知,肥胖会给人带来身心上的诸多危害和不便,身材不均也会影响人的美观和体质,还会是生活、工作等受到不同程度的影响,针对众多肥胖和身材不均者,目前一般的减肥方法油以下几种:1、服用减肥药、减肥茶以及减肥保健食品,这是现代较为普遍的方法,它是依靠抑制脑触体发育,使肥胖者产生“厌食感”,长期服用成瘾,能造成长期“厌食症”,它是在饥饿的基础上破坏人机体平衡,破坏脾胃吸收功能,达到减肥目的,这种方法有效日减肥可达一斤以上,但停药后即恢复原貌并增肥不止。2、剧烈运动与饥饿疗法。这种方法不仅耗时,而且伤身,停止运动、恢复正常饮食后,大多体重陡增,更甚于前,并且不易坚持,甚至感到痛苦,影响到人体正常代谢和消化功能。3、吸脂与超声波减肥。虽能够见效快,胆对人体内分泌、神经系统影响甚大,易引起机体能量代谢失调。操之过急,会危害人体健康。并且在吸脂后皮下组织空虚,常呈松弛状态,出现褶皱纹路,影响美观,而且,该方法不作内分泌和神经功能、气血循环上的调节,能量代谢障碍仍然存在,多余的卡路里仍然会以脂肪的形式重新堆积皮下的脂肪,再度肥胖。
肥胖在中医古籍中无专门的病名,但早在汉代以前就有相关症状、病因病机及危害性的记载。如《内经》“肥贵人”及“年五十,体重,且目不聪明矣”《金匾要略·血痹虚劳病脉证并治》“夫尊荣人骨弱肌肤盛”《素问·奇病论》“肥者令人内热,甘者令人中满”《素问·宣明五气论》“久卧伤气,久坐伤肉”等。认为过食肥甘及缺乏运动是肥胖的重要原因之一。肥胖病因复杂,饮食不节、情志失调、久坐少劳、脾胃阳虚、肝肾阴虚等均可致脾胃功能失调,形成肥胖。肥胖症的病机特点,古人认为多与“痰湿”及“脾虚”或气虚有关,其中“痰湿”为其标,“脾虚”、“气虚”为其本。如《仁斋直指方》曰“肥人气虚生寒,寒生湿,湿生痰……故肥人多寒湿、朱丹溪云“肥白人多湿”、“肥白人多痰饮”汪昂曰“肥人多痰而经阻,气不运也”。脾虚痰湿常常会使人纳呆,不欲食,但多数肥胖患者却消谷善饥。古人认为消谷善饥是因热而成“脾胃积热,消谷善饥。”故而《脾胃论》将肥胖分为“脾胃俱旺”和“脾胃俱虚”两型,认为“脾胃俱旺,则能食而肥脾胃俱虚,则不能食而肥或少食而肥,虽肥而四肢不举”,其本质上都是脾胃功能的失调。纵观历代医家文献,似乎此说最为可信。现代文献多从古说,亦有发挥。陈氏认为痰湿体质肥胖患者多夹“血痕”,提出胖人多痕,肥胖与血痕证相关的认识。这符合中医久病多虚、久病多痕的观点。一般认为肥人多气虚、多痰湿,但随着病程的延长,气虚血痕或痰寮互结是病理发展的必然结果。临床上有人以活血化痕方法治疗肥胖症也取得了较好的疗效。如大黄此类兼具通便与活血化痕功效的药物是目前治疗肥胖最常用的药物。综合以上,可以概括地讲,肥胖是各种因素导致脾胃俱强或俱弱,痰湿、痕血、膏脂等病理产物异常积聚的结果。肥胖症治疗以调理脾肾和脾胃为主,根据临床表现兼化湿、祛痰、利水、活血、润导、疏肝利胆、健脾、温阳等法,这与西医的治法采用控制饮食、加强运动、提高能量消耗、促进脂肪动员与分解等方法,本质上是一致的。这为中西医结合治疗肥胖症奠定了理论基础。基于此理论本方选用当归,黄芪补气补血,提高免疫力;番泻叶,苍术,白术,大黄,通便与活血化淤;泽泻,夏枯草,郁李仁,瓜蒌仁疏肝补气益胆,山楂开胃;丹皮清热去火;绞股蓝,威灵仙通气健脾;荷叶,苦瓜减肥消脂;诸药合用活血化瘀,祛痰湿,补裨益气,能达到减肥不伤元气的目的。
当归其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。
白术味苦、甘,温。归脾、胃经。主治健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。白术对瘤细胞有细胞毒作用,能降低瘤细胞的增殖率,减低瘤组织的侵袭性,提高机体抗肿瘤反应的能力。《药性论》载其:君,味甘,辛,无毒。能主大风痹,多年气痢,心腹胀痛,破消宿食,开胃,去痰涎,除寒热,止下泄。主面光悦,驻颜,去黑。治水肿胀满,吐呕逆,腹内冷痛,吐泻不住,及胃气虚冷痢。
大黄苦,寒。归脾、胃、大肠、肝、心包经。功能主治泻热通肠,凉血解毒,逐瘀通经。用于实热便秘,积滞腹痛,泻痢不爽,湿热黄疸,血热吐衄,目赤,咽肿,肠痈腹痛,痈肿疔疮,瘀血经闭,跌打损伤,外治水火烫伤;上消化道出血。酒大黄善清上焦血分热毒。用于目赤咽肿,齿龈肿痛。熟大黄泻下力缓,泻火解毒。用于火毒疮疡。大黄炭凉血化瘀止血。用于血热有瘀出血者。《本草新编》:大黄性甚速,走而不守,善荡涤积滞,调中化食,通利水谷,推陈致新,导瘀血,滚痰涎,破症结,散坚聚,止疼痛,败痈疽热毒,消肿胀,俱各如神。欲其上升,须加酒制;欲其下行,须入芒硝;欲其速驰,生用为佳。”
番泻叶甘、苦,寒。归大肠经。功能主治泻热行滞,通便函,利水。用于热结积滞,便秘腹痛,水肿胀满。1.泻下作用本品对小鼠、大鼠、家兔等多种动物及人均有显著的泻下作用,小鼠和兔于药后2-4h致泻,人口服后约6h引起泻下。本品致泻有效成分主要为番泻甙A和B,尤其是番泻甙A,番泻甙C虽致泻作用与A相近然含量很少。番泻甙A20mg/kg即可引起小鼠泻下。但倘于A中混入20%的C,则可使番泻甙A的作用增强1.6倍。番泻甙于小肠可以有部分吸收,后经血流或胆汁进入大肠,而主要则由小肠直接进入大肠,在肠内细菌作用下经水解、还原等变化成为大黄酸蒽酮或大黄酸蒽酮-8-葡萄糖甙。由于直接注入大黄酸蒽酮的泻下作用不受影响,且可见肠内大黄酸蒽酮的生成量显著减少,故认为大黄酸蒽酮才是番泻甙引起泻下的真正成分。另一方面,在翻转小肠和结肠囊番泻甙可阻止葡萄糖和Na的跨肠壁转运,表明抑制肠道对葡萄糖、钠和水的吸收,增加肠腔内容积继而刺激肠壁反射性地使小肠和结肠蠕动增强,也可能是其致泻机制之一,且小肠也是其泻下成分的作用部位。
泽泻味甘,性寒。归肾、膀胱经。功能主治利小便,清湿热。用于小便不利,水肿胀满,泄泻尿少,痰饮眩晕,热淋涩痛;高血脂。按《神农本草经》记载,泽泻初服可让人肥健,久服则可使人轻身。这说明,短期对人产生的效果可能与长期效果相反。能调整体重,自然先可以调整人的代谢功能。所以泽泻可以用于消渴病人。临床虽有时用在复方中,还是觉得泽泻有一些作用特点。《本草纲目》:“宗曰:泽泻之功,长于行水。张仲景治水蓄渴烦,小便不利,或吐或泻,五苓散主之,方用泽泻,故知其长于行水。”
黄芪以补虚为主,能补气固表,利尿托毒,排脓,敛疮生肌。用于气血不足、疮疡内陷、脓成不溃或久溃不敛者。黄芪具有很好的托毒生肌的功能,即久不愈合的脓肿化脓生肌。现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,因此还能用于预防某些传染病的发生。《本草逢原》载:“黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。”是增进抵抗力和防御疾病的良药。
郁李仁性辛、苦、甘,平。归脾、大肠、小肠经。功能主治润燥滑肠,下气,利水。用于津枯肠燥,食积气滞,腹胀便秘,水肿,脚气,小便不利。用于肠燥便秘。郁李仁体润滑降,具缓泻之功,善导大肠燥秘,常配合火麻仁、瓜蒌仁同用。用于小便不利、水肿、脚气等症。郁李仁又能利小便而退水肿,对水肿腹满、二便不利者,常用以配生苡仁、冬瓜皮等同用。
苍术性辛、味苦,温。归脾、胃、肝经。功能主治燥湿健脾,祛风散寒,明目。用于脘腹胀满,泄泻水肿,脚气痿躄,风湿痹痛,风寒感冒,夜盲。对心血管系统的影响显示,苍术对蟾蜍心脏有轻度抑制作用,对蟾蜍后肢血管有轻度扩张作用。苍术浸膏小剂量静脉注射,可使家兔血压轻度上升,大剂量则使血压下降。苍术燥湿健脾功效相关的药理作用为调整胃肠运动功能、抗溃疡、保肝。抑菌等。苍术主要有效成分是以β-桉叶醇及茅术醇为代表的挥发油。苍术对血糖的影响,抗缺氧、中枢抑制、抗肿瘤、促进骨骼钙化及对心血管系统的影响等作用,则是其药理作用的现代研究进展。
苦瓜性苦,寒。归脾、胃、心、肝经。清热祛心火,解毒,明目,补气益精,止渴消暑,治痈。促进饮食、消炎退热,苦瓜中的苦瓜甙和苦味素能增进食欲,健脾开胃;所含的生物碱类物质奎宁,有利尿活血、消炎退热、清心明目的功效;具有很好的减肥作用。
瓜蒌仁气微,味甘、微苦涩。功能主治润肺化痰,滑肠通便。用于咳燥痰粘,肠燥便秘。是化痰祛湿的良药。
荷叶味苦辛微涩、性凉,归心、肝、脾经;清香升散;具有消暑利湿,健脾升阳,散瘀止血的功效;主治暑热烦渴,头痛眩晕,水肿,食少腹胀,泻痢,白带,脱肛,吐血,衄血,咯血,便血,崩漏,产后恶露不净,损伤瘀血。中药现代研究结果表明,荷叶有降血脂作用。荷叶碱是荷叶中提取的生物碱,荷叶碱可扩张血管,清热解暑,有降血压的作用,同时还是减肥的良药。有资料报道,荷叶中的生物碱有降血脂作用,且临床上常用于肥胖症的治疗。荷叶简减肥原理,即服用后在人体肠壁上形成一层脂肪隔离膜,有效阻止脂肪的吸收,从根本上减重,并更有效的控制反弹。
枳壳苦、辛、酸,温。归脾、胃经。功能理气宽中,行滞消胀。用于胸胁气滞,胀满疼痛,食积不化,痰饮内停;胃下垂,脱肛,子官脱垂。《本草经疏》:枳壳,气味所主,与枳实大略相同。但枳实形小,其气全,其性烈,故善下达;枳壳形大,其气散,其性缓,故其行稍迟,是以能人胸膈肺胃之分及入大肠也。其主风痒麻痹,通利关节,止风痛者,盖肺主皮毛,胃主肌肉,风寒湿入于二经,则皮肤瘙痒,或作痛,或麻木,此药有苦泄辛散之功,兼能引诸风药入于二脏,故为治风所需,风邪既散,则节自然通利矣。其疗劳气咳嗽,背膊闷倦者,盖亦指风寒郁于上焦,则肺气滞而为闷倦咳嗽。
山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。山楂中含有山萜类及黄铜类等药物成分,具有显著的扩张血管及降压作用,有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能。《本草经疏》:山楂,《本经》云味酸气冷,然观其能消食积,行瘀血,则气非冷矣。有积滞则成下痢,产后恶露不尽,蓄于太阴部分则为儿枕痛。山楂能入脾胃消积滞,散宿血,故治水痢及产妇腹中块痛也。大抵其功长于化饮食,健脾胃,行结气,消瘀血。
绞股蓝除含有甾醇、糖份、色素外,还有50多种皂苷,包括四环三萜化合物,其中七叶胆皂甙III、IV、VII、XII四种,分别与人参皂甙Rb1、Rb3、Rd、F2是同一物质,Rd是人参的8倍,不含性激素的富硒植物。;其酸水解产物与人参皂甙的酸水解产物——人参二醇具有相同的理化性质。这在非五加科的植物中是非常罕见的,因而被誉为“第二人参”。七叶胆皂甙对肝癌、肺癌、子宫癌、皮肤癌等癌细胞的增殖,有明显的抑制作用。日本药理试验和临床应用证实,绞股蓝不仅对人体有滋补、镇静、催眠、抗紧张、促食欲、降血脂、降胆固醇、降转氨酶、延缓衰老等作用,还能防止正常细胞癌化并使癌细胞转化为正常细胞。临床上可用于肺癌、胃癌、肝癌、食道癌、胆囊癌、直肠癌、胰腺癌、乳腺癌和子宫癌等20多种癌症,还能防治心血管疾病,改善肥胖症,防治乙型肝炎、肝硬化、胃和十二指肠溃疡,治疗偏头痛、白发、失眠症、不定愁诉症等。从而展现了广阔的药用前景。绞股蓝主要成份为绞股蓝皂甙(GP),与人参皂甙一样,可使血小板聚集,防止动脉粥样硬化,提供细胞充足养份。保证血流通畅。降低心脑血管发病率。因为它还含有与人参皂甙不同的皂甙,所以绞股蓝又具有镇静,滋阴之功效,无毒副作用,宜长期食用。
威灵仙辛咸,温,有小毒。入肺、肾二经祛风除湿,通络止痛,消痰水,散癖积。主治痛风顽痹、风湿痹痛,肢体麻木,腰膝冷痛,筋脉拘挛,屈伸不利,脚气,疟疾,症瘕积聚,破伤风,扁桃体炎,诸骨鲠咽。《唐本草》:腰、肾、脚膝、积聚、肠内诸冷病,积年不瘥,服之效。《开宝本草》:主诸风,宣通五藏,去腹内冷滞,心隔痰水久积,症瘕痃癣气块,膀胱宿脓恶水,腰膝冷疼及疗折伤。
羌活性辛、味苦,温。归膀胱、肾经。功能主治散寒,祛风,除湿,止痛。用于风寒感冒头痛,风湿痹痛,肩背酸痛。用于风寒感冒,头痛身疼。本品辛温,气雄而散,发表力强,主散太阳经风邪及寒湿之邪,有散寒祛风、胜湿止痛之功,故善治风寒湿邪袭表,恶寒发热、肌表无汗、头痛项强、肢体酸痛者,常与桃仁、细辛、苍术、川芎等药同用。
薏仁是常用的中药.又是普遍、常吃的食物,性味甘淡微寒,有利水消肿、健脾去湿、舒筋除痹、清热排脓等功效,为常用的利水渗湿药。薏仁又是一种美容食品,常食可以保持人体皮肤光泽细腻,消除粉刺、斑雀、老年斑、妊娠斑、蝴蝶斑,对脱屑、痤疮、皲裂、皮肤粗糙等都有良好疗效。薏仁是补身药用佳品。据医药部门化验分析,薏仁含蛋白质16.2%,脂肪4.6%,糖类79.2%。冬天用薏仁炖猪脚、排骨和鸡,是一种滋补食品。夏天用薏仁煮粥或作冷饮冰薏仁,又是很好的消暑健身的清补剂。薏仁的种仁和根又能入药治病。李时珍在《本草纲目》中记载:薏仁能″健脾益胃,补肺清热,去风胜湿。炊饭食,治冷气。煎饮,利小便热淋。″近年来,大量的科学研究和临床实践证明,薏仁还是一种抗癌药物,初步鉴定,它对癌症的治抑率可达35%以上。难怪桂林地区有首民谣这样唱道:″薏仁胜过灵芝草,药用营养价值高,常吃可以延年寿,返老还童立功劳。″
夏枯草苦、辛,寒。多用来散结消肿,治瘰疬、瘿瘤、乳痈肿痛。《本草从新》载其:治瘰疬、鼠瘘、瘿瘤、症坚、乳痈、乳岩。夏枯草为清肝火、散郁结的要药,它所主治的大多是肝经的病症。本品配以菊花、决明子,可清肝明目,治目赤肿痛、配以石决明、钩藤,可平降肝阳,治头痛、头晕;配以玄参、贝母、牡蛎等品,可软坚散结,治瘰历结核。
丹皮性寒,味苦、辛。具有清热凉血,活血行瘀。用于温毒发斑、痈肿疮毒。《本草纲目》载:“治血中伏火,除烦热。”此药含牡丹酸、牡丹酸甙、牡丹酚原甙、芍药甙、挥发油及植物甾醇等,丹皮酚及糖甙成分均有抗炎作用。丹皮酚有镇静、降温、解热、镇痛、解痉等中枢抑制作用。是非常好的镇痛,清热,化淤良药。
外用药物中败酱草,鱼腥草解毒除湿,天南星去水肿,旱莲草凉血清热;鸡血藤,丹参活血化瘀消脂;防己,细辛,冰片消肿去脂;附子升阳除湿,诸药合用减肥很有效。
败酱草性味苦平,具有清热解毒、排脓破瘀的功效。能医肠痈、下痢、赤白带下、产后瘀滞腹痛、目赤肿痛。入胃、大肠、肝经。主治清热解毒,消痈排脓,活血行瘀。用于肠痈、肺痈及疮痈肿毒,实热瘀滞所致的胸腹疼痛,产后瘀滞腹痛等症。
旱莲草性味甘酸,凉血,止血,补肾,益阴。治吐血,咳血,衄血,尿血,便血,血痢,刀伤出血,须发早白,白喉,淋浊、带下,阴部湿痒。
鱼腥草,中医认为其味辛、性寒凉,能清热解毒、排痛消肿疗疮、利尿除湿、健胃消食,用治实热、热毒、湿邪、疾热为患的肺痈、疮疡肿毒、痔疮便血、脾胃积热等,单用或配伍复方,内服外用或民间多种食疗方法的使用均疗效确切。药理研究,鱼腥草主含挥发油,癸酰乙醛鱼腥草素等多种成份,对各种致病杆菌、球菌、流感病毒、钩端螺旋体等有抑制抗菌作用,并能提高人体免疫调节功能。
细辛味辛,温祛风,散寒,行水,开窍。治风冷头痛,鼻渊,齿痛,痰饮咳逆,风湿痹痛。《药性论》载:治咳逆上气,恶风,风头,手足拘急,安五脏六腑,添胆气,去皮风湿庠,能止眼风泪下,明目,开胸中滞,除齿痛,主血闭,妇人血沥腰痛。细辛具有强心、抗心肌缺血、升高血压作用。离体实验表明,细辛挥发油对兔、脉鼠心脏有明显的兴奋作用,表现为正性肌力,正性频率作用,并能增加冠脉流量。对犬实验性心源性休克,细辛能提高其平均动脉压、左室压峰值和冠状血窦流量等作用,其作用强度与多巴胺相似,但其不加快心率。
冰片用于目赤肿痛,喉痹口疮。冰片苦寒,有清热止痛、消肿之功,为五官科常用药。治疗咽喉肿痛、口舌生疮,常与硼砂、朱砂、玄明粉共研细末,吹敷患处,如冰硼散。治疗风热喉痹,用于疮疡肿痛,溃后不敛。本品亦有清热解毒、防腐生肌作用。是外科的良药佳品。
防己苦,寒。归膀胱、肺经。主治利水消肿,祛风止痛。用于水肿脚气,小便不利,湿疹疮毒,风湿痹痛;高血压。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。
鸡血藤性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;凌霄花,鸡血藤内服是治疗血淤不散,养血化淤活血的良药。
天南星有祛风定惊、消肿散结的功效。苦、辛,温;有毒。归肺、肝、脾经。《开宝本草》载其:主中风,除痰,麻痹,下气,破坚积,消痈肿,利胸膈,散血堕胎。少量运用外科可祛肿散淤。
附子辛、甘,大热;有毒。归心、肾、脾经回阳救逆,补火助阳,逐风寒湿邪。用于亡阳虚脱,肢冷脉微,阳痿,宫冷,心腹冷痛,虚寒吐泻,阴寒水肿,阳虚外感,寒湿痹痛,阴疽疮疡。其实附子功效、主治甚广,附子具有回阳救逆,补火助阳,逐风寒湿邪之功效。主治亡阳虚脱,肢冷脉微,阳痿,宫冷,心腹冷痛,虚寒吐泻,阴寒水肿,寒湿痹痛等。《本草汇言》云:“附子,回阳气,散阴寒。......凡属阳虚阴极之候,肺肾元热证者,服之有起死之殊功。”
本发明内服药物为蜜炼丸剂的制作过程为:苍术2000g,白术2000g,大黄2000g,当归2000g,泽泻2000g,丹皮2000g,郁李仁2000g,荷叶2000g,绞股蓝2000g,黄芪2000g,枳壳2000g,威灵仙2000g,夏枯草2000g,苦瓜2000g,番泻叶2000g,瓜蒌仁2000g,山楂2000g,羌活2000g,薏仁2000g。把药材加水浸泡30分钟至1小时,加热煮沸30分钟,过滤,滤液备用;滤渣加水,第二次加热,煮沸30分钟,再过滤,滤液备用;滤渣再加水,第三次加热煮沸40分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却成粉末状与蜂蜜混和在一起搓成细条;以每5g为一丸腊封包装。
本发明内服药物为胶囊剂的制作过程为:取苍术2000g,白术2000g,大黄2000g,当归2000g,泽泻2000g,丹皮2000g,郁李仁2000g,荷叶2000g,绞股蓝2000g,黄芪2000g,枳壳2000g,威灵仙2000g,夏枯草2000g,苦瓜2000g,番泻叶2000g,瓜蒌仁2000g,山楂2000g,羌活2000g,薏仁2000g。加10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度约为1.08(20℃);上述滤液经体积为10L的大孔吸附树脂柱,先用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,得到组份药;装入胶囊制为胶囊剂,每粒胶囊装0.3g。可以每12粒为一板。
本发明内服药物为片剂的制作过程为:苍术2000g,白术2000g,大黄2000g,当归2000g,泽泻2000g,丹皮2000g,郁李仁2000g,荷叶2000g,绞股蓝2000g,黄芪2000g,枳壳2000g,威灵仙2000g,夏枯草2000g,苦瓜2000g,番泻叶2000g,瓜蒌仁2000g,山楂2000g,羌活2000g,薏仁2000g,将所述药物切碎加入到多功能提取罐内,加入3000g的水浸泡30~40分钟,煎煮1.5小时后,取出第一次煎煮液备用;药渣加入3000g的水煎煮1小时后,取出第二次煎煮液,将两次煎煮液合并过滤,滤液减压浓缩至重量份数比为1000g的溶液,静置沉淀24~36小时,吸取上清液,加热至40~50℃后加入淀粉3000g,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,制片、干燥、成型、分装。可以每一百片为一瓶包装。每天服用三次,每次3片。
本发明外用药物的剂型为涂抹剂时,其制备方法包括以下步骤:先将冰片3000g研细备用;按照所述份数比将天南星3000g,附子3000g用95%乙醇浸泡三次,每次浸泡时间分别为2小时、1小时、1小时;每次浸泡后80~85℃热提去其毒性;所用乙醇与附子,天南星总重量相比分别为:第一次10倍量、第二次6倍量、第三次6倍量;合并三次乙醇提取液,浓缩至相对密度为1.08的浓缩液,静置备用,将细辛3000g,防己3000g,旱莲草3000g,丹参3000g,鸡血藤3000,鱼腥草3000,败酱草3000g,按配比混合,常温下,与乙醇共同浸渍15~30天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,将滤液与上述浓缩液合并加热,浓缩至糊状,放入烘箱烘干后冷却,研磨成细粉,加入冰片细粉和凡士林调和成糊状。
本发明膏药施于皮肤表面,借助经络通络作用发挥药物的通经活络、去瘀行滞、开窍透骨、驱风散寒的功能,缓解风湿、类风湿、骨质增生、肩周炎、跌打损伤引起的疼痛康复。具有作用迅速,疗效确切,价廉易得,携带、贮藏、使用方便的优点,深受广大人民群众欢迎。
外用药物毒性实验
急性经口毒性试验:该品按卫生部《化妆品卫生规范》(2002年版)“急性经口毒性试验中一次限量试验法”,一次经口给予沈阳种小鼠,体重18g~22g,20只,灌胃剂量5000mg/kg体重,灌胃量20ml/kg,观察15天,试验动物未发现中毒表现、无死亡,处死后解剖未明显异常,判断该品对小鼠急性经口毒性属实际无毒级。
急性经皮毒性试验:该品依据卫生部《化妆品卫生规范》(2002)第二部分“急性经皮毒性试验”一次限量试验法,SD大鼠20只,雌雄各半,体重90g~180g,一次经皮涂抹5000mg/kg体重剂量,观察15天,未发现明显中毒症状、无死亡,动物大体解剖未见异常,判断该品对大鼠急性经皮毒性属实际无毒级。
急性皮肤刺激试验:该品依据卫生部《化妆品卫生规范》(2002)第二部分“皮肤刺激性/腐蚀性试验”中6.3节,日本大耳白兔雄性4只,体重2kg~3kg,取该品0.5g直接涂抹在动物左侧皮肤上(另一侧作为对照),采用封闭试验,敷用时间4小时,试验结束后用温水冲洗残留受试物,于除去受试物后1h、24h、48h和72h分别观察动物受试区和对照区的皮肤反应,最高积分均值为“0”,判断该品对动物皮肤无刺激性。
内服药物长期毒性实验:
本发明中药制剂对小鼠按7.81、18.34和40.11g生药/kg连续用药12周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药制剂对大鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药12周及停药3周后,大鼠各脏器均无明显改变。说明本发明中药制剂对大鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
药效学实验
受试药物:本发明中药减肥胶囊,每粒重0.6g(每粒相当于原生药50g),临床剂量为成人1g(原生药)/kg。取中药复方减肥胶囊4粒,除去囊壳,将内容物加蒸馏水至100mL,混匀后所成的药液(每100mL含原生药200g)供大剂量组用,并将其等比例稀释成50%、25%药液分别供中剂量组(每100mL含原生药100g)、小剂量组(每100mL含原生药50g)用。
阳性对照药:盐酸芬氟拉明片(Tablets Fenfluramine Hy2drochloride,TFH),规格:每片含盐酸芬氟拉明20mg。临床剂量为每次1片,每天3次。上海医药工业研究院亚东药业公司宝山药厂产品,沪卫药准字(1995)035001,批号970111。
配制:取TFH 100mg加蒸馏水至100mL,混匀后即成0.1%药液供芬氟拉明组用。
受试动物:试验用刚断奶的SD大鼠,雌雄各半,共60只,体重50~55g,由江苏省抗生素工业研究所动物中心提供,检疫后备用。
1.3试剂
胆固醇(CHO)测定试剂盒(CHOD2PAP法),批号:960724;甘油三酯(TG)测定试剂盒(GP02POD法),批号:960722;高密度脂蛋白(HDL)试剂盒(Cholesterol2HDL法),批号:961031。以上均为北京化工厂临床试剂分厂产品。
1.4仪器
日本岛津UV2730自动生化比色仪;日本津田EB23200D精密电子天平(精度0.1g)。
1.5饲料
普通饲料:大麦粉20%、脱水菜(去除水分的包心菜)10%、豆粉20%、酵母1%、玉米粉16%、麸皮16%、鱼粉10%、食盐2%。营养饲料:100g普通饲料中加入奶粉10g、猪油10g、鸡蛋1只、浓缩鱼肝油适量(含维生素A17000U、维生素D11700U)、新鲜黄豆芽250g。
2.方法
2.1造模及分组
SD大鼠按体重随机分为正常对照组、模型对照组、本发明中药减肥胶囊高、中、低3个剂量组(分别相当于临床推荐剂量的20倍、10倍、5倍)和阳性西药对照组(相当于临床推荐剂量的10倍)等6组。正常对照组动物喂予普通饲料,其余各组均喂予营养饲料。供应饲料的量为第1、2周内每鼠每天13g,以后每周增加2g,至第6周止。每日饲料分2次供给,吃完后不再添加;喂饲45天后,体重较普通饲料喂养的同龄大鼠增加将近1倍。
2.2给药时间及方法
采用等容积不等浓度药液给药,灌胃容积10mL/kg。每天灌胃1次,连续4周,每周称重1次,根据体重调整营养饲料量和给药量。
2.3评价指标
(1)体重和Lee’s指数值测定:处死前,在麻醉下准确测量体长(从鼻至肛门的长度),然后计算Lee’s index值。计算公式:Lee’s指数=[体重(g)×103]1/3/体长(cm)。(2)肾周围、腹腔脂肪重量测定:放血后,分别剖取肾周围及腹腔内全部脂肪,称取湿重。(3)生化测定:血清总胆固醇、甘油三酯、高密度脂蛋白、葡萄糖。
2.4统计方法
在计算机上采用SPSS进行统计处理,计量资料用.x±s表示。实验结果采用模型组与空白组进行比较,各给药组与模型组进行两两比较。
3结果
3.1本发明中药减肥胶囊对实验鼠体重的影响(见表1)
表1中药复方减肥胶囊对实验鼠体重的影响(.x±s)
与正常对照组比较,##P<0.01;与模型对照组比较,*P<0.05
从表1可以看出,中药减肥胶囊给药组体重与模型组比较有减低趋势,其中中药减肥胶囊中剂量组体重与模型组比较(在第7、第8周时)有显著性差异(P<0.05)。
3.2中药减肥胶囊对试验鼠Lee‘s指数和脂肪湿重
指数的影响(见表2)
表2中药减肥胶囊对试验鼠Lee‘s指数和脂肪湿重指数的影响(x±s)
组别 | n | 剂量(g/kg) | Lee’s指数值 | 脂肪湿重(g/100g) |
正常对照组 | 10 | / | 307.7±7.6 | 2.1±0.6 |
肥胖模型组 | 10 | / | 318.6±7.8 | 4.5±1.1 |
阳性对照组 | 10 | 10mg/kg | 299.4±21.85 | 2.4±0.8 |
低剂量组 | 10 | 50 | 307.5±9.81 | 2.7±1.0 |
中剂量组 | 10 | 100 | 311.6±7.67 | 2.7±0.81 |
高剂量组 | 10 | 200 | 308.4±15.7 | 2.8±1.0 |
与正常对照组比较,##P<0.01;与模型对照组比较,**P<0.01
从表2可以看出,中药减肥胶囊给药组Lee’s指数与模型组相比有降低趋势,其中中药减肥胶囊低剂量组Lee’s指数值与模型组比较有极显著性差异(P<0.01)。中药减肥胶囊3个剂量组脂肪湿重指数与模型组比较均有极显著性差异(P<0.01)。
3.3中药减肥胶囊对试验鼠血Cho、TG、HDL2C及GLU水平的影响(见表3)
表3中药减肥胶囊对试验鼠血中Cho、TG、HDL2C、GLU水平的影响(.x±s)
组别 | n | 剂量(g/kg) | Cho(mmol/L) | TG(mg/dL) | HDL2C(mg/dL) | GLU(mmol/L) |
正常对照组 | 10 | / | 1.6±0.56 | 62.8±21.9 | 45.7±10.7 | 4.7±1.2 |
肥胖模型组 | 10 | / | 1.9±0.2 | 154.4±54.7 | 40.9±21.5 | 6.1±0.9 |
阳性对照组 | 10 | 10mg/kg | 2.1±0.61 | 97.7±42.27 | 40.5±9.3 | 5.0±0.6 |
低剂量组 | 10 | 50 | 1.9±0.4 | 71.2±38.6 | 52.7±11.08 | 4.6±0.8 |
中剂量组 | 10 | 100 | 1.9±0.46 | 83.3±34.8 | 43.3±13.59 | 5.2±1.22 |
高剂量组 | 10 | 200 | 1.5±0.5 | 61.3±34.31 | 42.3±14.3 | 4.8±1.47 |
与正常对照组比较,##P<0.01;与模型对照组比较:*P<0.05,**P<0.01
从表3可以看出,本发明中药减肥胶囊给药组Cho、TG、GLU与模型组比较有降低趋势,其中本发明中药减肥胶囊高剂量组Cho与模型组比较有显著性差异(P<0.05);本发明中药减肥胶囊3个剂量组TG与模型组比较有极显著性差异(P<0.01);本中药减肥胶囊低剂量组GLU与模型组比较有极显著性差异(P<0.01),本发明减肥胶囊高剂量组GLU与模型组比较有显著性差异(P<0.05);本发明中药减肥胶囊给药组HDL2C与模型组比较有增加趋势,其中本发明中药减肥胶囊低剂量组HDL2C与模型组比较有显著性差异(P<0.05)。
由此可以得出结论本发明中药减肥内服物具有明显的减肥效果。
典型病例1:患者张某,女,34岁,115公斤,3尺3的腰围,诊见痰浊肥胖。症见气虚胸闷、嗜睡懒动、苔白腻、舌胖、脉滑,使用本发明中药组合物,内服外用配合使用.内服药物为:苍术20g,白术10g,大黄20g,当归15g,泽泻10g,丹皮10g,郁李仁20g,荷叶20g,绞股蓝15g,黄芪20g,枳壳10g,威灵仙10g,夏枯草10g,苦瓜20g,番泻叶20g,瓜蒌仁15g,山楂20g,羌活10g,薏仁20g;
所述外用药物中各种组份的重量份数比为:细辛30g,防己20g,冰片20g,旱莲草30g,丹参30g,附子15g,天南星20g,鸡血藤30g,鱼腥草20g,败酱草20g。外用药物每日涂抹于脂肪堆积部位,并按摩至皮肤发热为止,一天三次。用药十天就减4寸,整体变化很大,曾经腹部胀满,拒按,腹部大的看不到自己的脚部,身体沉重,用药后症状消失,瘦身很多,并且精神状态非常好。随访2年未复发。
典型病例2:患者周某,男,42岁,脂肪肝,嗜食肥甘厚味导致的肥胖。症见大腹便便、动则喘息,苔黄厚、脉实,3尺7的腰围,神情抑郁,使用本发明中药组合物,内服外用配合使用.内服药物为:苍术20g,白术10g,大黄20g,当归10g,泽泻10g,丹皮10g,郁李仁20g,荷叶10g,绞股蓝15g,黄芪10g,枳壳15g,威灵仙20g,夏枯草10g,苦瓜20g,番泻叶20g,瓜蒌仁15g,山楂20g,羌活10g,薏仁15g;
所述外用药物中各种组份的重量份数比为:细辛30g,防己20g,冰片20g,旱莲草30g,丹参20g,附子15g,天南星20g,鸡血藤20g,鱼腥草30g,败酱草20g。外用药物每日涂抹于脂肪堆积部位,并按摩至皮肤发热为止,一天三次。用药15天,减了3寸,精神状态转好。随访三年,已慢慢达到正常体重。
典型病例3:患者钱某,女,30岁,118公斤,诊见肥胖兼肝郁气滞或血瘀者。症见肥胖兼有胁痛、急躁、眩晕、倦怠、腹胀、舌苔黄、脉弦,使用本发明中药组合物,内服外用配合使用.内服药物为:苍术20g,白术10g,大黄20g,当归10g,泽泻20g,丹皮20g,郁李仁20g,荷叶20g,绞股蓝15g,黄芪10g,枳壳15g,威灵仙10g,夏枯草10g,苦瓜20g,番泻叶20g,瓜蒌仁15g,山楂20g,羌活20g,薏仁15g;
所述外用药物中各种组份的重量份数比为:细辛30g,防己20g,冰片20g,旱莲草30g,丹参30g,附子15g,天南星20g,鸡血藤30g,鱼腥草30g,败酱草30g。外用药物每日涂抹于脂肪堆积部位,并按摩至皮肤发热为止,一天三次。效果:使用后,腹部皮肤褶皱减少,变得细腻光滑,腹部有发热感,脐周热度明显,感觉腹部脂肪变薄,赘肉减少,腹部变平坦,腹胀消失,大便通畅,调理肠胃功能效果明显,睡眠良好。使用半年后回复正常体重。
60例患者男38例,女22例,年龄24-65岁,平均年龄45岁,排除继发性肥胖均为单纯性肥胖,体重指数(BMI)≥25Kg/m。60例患者随机分为治疗组与对照组,每组30例。两组年龄、性别、BMI经统计学处理,无显著差异,具有可比性(P>0.05)
治疗和观察方法治疗方法:治疗组饭前口服本发明中药组合物胶囊剂,每日3次,每次5粒,疗程2个月。外用药物每日涂抹于脂肪堆积部位,并按摩至皮肤发热为止,一天三次。对照组不服用药物。两组都停止饮酒、停喝含糖碳酸饮料,停止剧烈运动,适当控制饮食量。观察方法:治疗前后与中间各检测一次体重。治疗期间观察精神、睡眠、症状、大小便正常与否。
疗效标准:显效;体重下降10公斤以上者;有效:体重下降了5公斤以上者;无效:体重下降未超过3公斤。
结果:治疗组显效22例(73.3%),有效6例(20%),无效2例(6.7%),总有效率为93.3%。对照组有效3例(10%),无效27例(90%)。两组经统计学处理,具有显著差异(P>0.01).
治疗期间,患者未见不良反应,无腹泻与身体不适。
Claims (4)
1.一种中药减肥组合物,其特征在于,由内服药物和外用药物组成,所述内服药物中各种组份的重量份数比为:苍术10~20份,白术10~20份,大黄10~20份,当归10~20份,泽泻10~20份,丹皮10~20份,郁李仁10~20份,荷叶10~20份,绞股蓝10~20份,黄芪10~20份,枳壳10~20份,威灵仙10~20份,夏枯草10~20份,苦瓜10~20份,番泻叶10~20份,瓜蒌仁10~20份,山楂10~20份,羌活10~20份,薏仁10~20份;
所述外用药物中各种组份的重量份数比为:细辛10~30份,防己10~30份,冰片10~30份,旱莲草10~30份,丹参10~30份,附子10~30份,天南星10~30份,鸡血藤10~30份,鱼腥草10~30份,败酱草10~30份;
所述中药减肥组合物中内服药物的剂型为胶囊剂,其制备方法包括以下步骤:
a.将所述组份粉碎后加入10倍量乙醇,加热回流提取3次,每次加热为2小时;
b.将3次提取液合并后,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08,所述滤液流经体积为10L的吸附树脂柱吸附;
c.吸附之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到组份药粉,装入胶囊制为胶囊剂;
所述中药减肥组合物中外用药物的剂型为涂抹剂,其制备方法包括以下步骤:先将冰片研细备用;按照所述份数比将天南星,附子用95%乙醇浸泡三次,每次浸泡时间分别为2小时、1小时、1小时;每次浸泡后80~85℃热提取;所用乙醇与附子,天南星总重量相比分别为:第一次10倍量、第二次6倍量、第三次6倍量;合并三次乙醇提取液,浓缩至相对密度为1.08的浓缩液,静置备用,将所述剩余组份按配比混合,投入粉碎机粉碎成细粉,细粉过筛后放入耐酸碱浸渍锅内,在常温下,与乙醇共同浸渍15~30天,将浸渍好的液体及药渣进行压榨过滤,分离后取滤液,将滤液与上述浓缩液合并加热,浓缩至糊状,放入烘箱烘干后冷却,研磨成细粉,加入冰片细粉和凡士林调和成糊状。
2.根据权利要求1所述中药减肥组合物,其特征在于,
所述内服药物中各种组份的重量份数比为:苍术10~15份,白术10~15份,大黄10~15份,当归10~15份,泽泻10~15份,丹皮10~15份,郁李仁10~15份,荷叶10~15份,绞股蓝10~15份,黄芪10~15份,枳壳10~20份,威灵仙10~20份,夏枯草10~20份,苦瓜10~20份,番泻叶10~20份,瓜蒌仁10~20份,山楂10~20份,羌活10~20份,薏仁10~20份;
所述外用药物中各种组份的重量份数比为:细辛10~20份,防己10~20份,冰片10~20份,旱莲草10~20份,丹参10~20份,附子10~20份,天南星10~20份,鸡血藤10~20份,鱼腥草10~20份,败酱草10~20份。
3.根据权利要求1所述中药减肥组合物,其特征在于,
所述内服药物中各种组份的重量份数比为:苍术10~20份,白术10~20份,大黄10~20份,当归10~20份,泽泻10~20份,丹皮10~20份,郁李仁10~20份,荷叶10~20份,绞股蓝10~20份,黄芪10~20份,枳壳10~15份,威灵仙10~15份,夏枯草10~15份,苦瓜10~15份,番泻叶10~15份,瓜蒌仁10~15份,山楂10~15份,羌活10~15份,薏仁10~15份;
所述外用药物中各种组份的重量份数比为:细辛15~25份,防己15~25份,冰片15~25份,旱莲草15~25份,丹参15~25份,附子15~25份,天南星15~25份,鸡血藤15~25份,鱼腥草15~25份,败酱草15~25份。
4.根据权利要求1所述中药减肥组合物,其特征在于,
所述内服药物中各种组份的重量份数比为:苍术15~20份,白术15~20份,大黄15~20份,当归15~20份,泽泻15~20份,丹皮15~20份,郁李仁15~20份,荷叶15~20份,绞股蓝15~20份,黄芪15~20份,枳壳15~20份,威灵仙15~20份,夏枯草15~20份,苦瓜15~20份,番泻叶15~20份,瓜蒌仁15~20份,山楂15~20份,羌活15~20份,薏仁15~20份;
所述外用药物中各种组份的重量份数比为:细辛10~25份,防己10~25份,冰片10~25份,旱莲草10~25份,丹参10~25份,附子10~25份,天南星10~25份,鸡血藤10~25份,鱼腥草10~25份,败酱草10~25份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100171697A CN101607051B (zh) | 2009-07-23 | 2009-07-23 | 一种中药减肥组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100171697A CN101607051B (zh) | 2009-07-23 | 2009-07-23 | 一种中药减肥组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101607051A CN101607051A (zh) | 2009-12-23 |
CN101607051B true CN101607051B (zh) | 2011-06-29 |
Family
ID=41481062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100171697A Expired - Fee Related CN101607051B (zh) | 2009-07-23 | 2009-07-23 | 一种中药减肥组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101607051B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015084973A1 (en) * | 2013-12-03 | 2015-06-11 | Li, Xiu-Min | Weight loss formulations, methods, and compositions based on traditional chinese medicine |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178873B (zh) * | 2011-04-23 | 2012-11-28 | 王效山 | 一种包括外用剂和内服剂相组合的中药减肥制剂及其制备方法 |
CN102578576A (zh) * | 2012-02-27 | 2012-07-18 | 苏州爱斯欧蒂生物科技有限公司 | 减肥多效保健品 |
CN103536852A (zh) * | 2013-10-23 | 2014-01-29 | 罗田县精神卫生中心 | 一种治疗精神疾病的药物组合物及其用途 |
CN104491579A (zh) * | 2014-12-18 | 2015-04-08 | 杨清兰 | 一种具有减肥功效的中药 |
CN104940717A (zh) * | 2015-05-29 | 2015-09-30 | 吴优 | 一种瘦身减肥脐贴及其制备方法 |
CN109893589A (zh) * | 2019-04-17 | 2019-06-18 | 湖南高迪信达生物科技有限公司 | 一种用于减肥降脂的纯天然植物药组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1097614A (zh) * | 1993-07-22 | 1995-01-25 | 贺世昌 | 一种健美减肥袋 |
CN1424102A (zh) * | 2002-12-27 | 2003-06-18 | 王�琦 | 一种减肥降脂中药制剂 |
CN1509750A (zh) * | 2002-12-25 | 2004-07-07 | 叶高瑞 | 一种番木瓜活性纤体生物制剂 |
CN1839978A (zh) * | 2006-01-26 | 2006-10-04 | 葛强 | 一种减肥美容的药物 |
CN101049451A (zh) * | 2007-05-16 | 2007-10-10 | 葛月云 | 复方制剂在治疗人类全身性骨折减肥抗衰老药物中的应用 |
-
2009
- 2009-07-23 CN CN2009100171697A patent/CN101607051B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1097614A (zh) * | 1993-07-22 | 1995-01-25 | 贺世昌 | 一种健美减肥袋 |
CN1509750A (zh) * | 2002-12-25 | 2004-07-07 | 叶高瑞 | 一种番木瓜活性纤体生物制剂 |
CN1424102A (zh) * | 2002-12-27 | 2003-06-18 | 王�琦 | 一种减肥降脂中药制剂 |
CN1839978A (zh) * | 2006-01-26 | 2006-10-04 | 葛强 | 一种减肥美容的药物 |
CN101049451A (zh) * | 2007-05-16 | 2007-10-10 | 葛月云 | 复方制剂在治疗人类全身性骨折减肥抗衰老药物中的应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015084973A1 (en) * | 2013-12-03 | 2015-06-11 | Li, Xiu-Min | Weight loss formulations, methods, and compositions based on traditional chinese medicine |
US10028985B2 (en) | 2013-12-03 | 2018-07-24 | Xiu-Min Li | Weight loss formulations, methods, and compositions based on traditional Chinese medicine |
Also Published As
Publication number | Publication date |
---|---|
CN101607051A (zh) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
CN102078473B (zh) | 一种治疗慢性乙型肝炎的中药制剂及其制备方法 | |
CN102886038B (zh) | 一种用于减肥的中药制剂及制备方法 | |
CN103690853B (zh) | 一种治疗湿烂型脚癣的中药制剂及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN101607051B (zh) | 一种中药减肥组合物及其制备方法 | |
CN101797326A (zh) | 一种治疗肠鸣腹泻的中药制剂及其制备方法 | |
CN102784363A (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN103041209B (zh) | 一种治疗肾阴虚的中药制剂及其制备方法 | |
CN102058715B (zh) | 一种治疗慢性前列腺炎的中药制剂及其制备方法 | |
CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
CN102000164B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN104689226A (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN102988675B (zh) | 一种治疗慢性前列腺炎的中药组合物及其制备方法 | |
CN104474500A (zh) | 一种补血调经的中药保健品及其制备方法 | |
CN103520655A (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
CN103749819B (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
CN105194421A (zh) | 一种夏枯草降血脂保健口服液及其制备方法 | |
CN104815037A (zh) | 一种治疗风湿蕴毒型慢性湿疹的药物及其制备方法 | |
CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
CN106540167A (zh) | 一种减肥中药 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN105943705A (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110629 Termination date: 20120723 |